Literature DB >> 17989709

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis.

B Patel1, S M Richards, J M Rowe, A H Goldstone, A K Fielding.   

Abstract

Avascular necrosis (AVN) is a serious complication of acute lymphoblastic leukaemia (ALL) therapy. Little is known of the scope and magnitude of this problem among adults with ALL. We analysed the incidence and risk factors for AVN in 1053 patients on the UKALLXII/ECOG2993 study. AVN affected 99 joints in 42 patients at a median of 2.2 years post-diagnosis, giving a crude incidence rate of 4.0%. Statistically significant risk factors for the development of AVN were age and treatment with chemotherapy. Patients receiving prolonged chemotherapy without stem cell transplant were at significantly greater risk of developing AVN than stem cell transplant recipients (P<0.00005). The actuarial incidence of AVN was 29% at 10 years in patients <20 years old compared to 8% at 10 years in those >20 years old; P=0.0004; odds ratio 0.28 (95% CI=0.14-0.56).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989709     DOI: 10.1038/sj.leu.2405032

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  Acute lymphoblastic leukemia of adulthood: progress or not?

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 2.  Cord blood--an alternative source for bone regeneration.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe
Journal:  Stem Cell Rev Rep       Date:  2009-08-04       Impact factor: 5.739

3.  Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia.

Authors:  Laura J Janke; Sara L Van Driest; Mary V Portera; Ravi V Atreya; Joshua C Denny; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Sima Jeha; Ching-Hon Pui; Mary V Relling; Seth E Karol
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

4.  Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.

Authors:  Leonard A Mattano; Meenakshi Devidas; James B Nachman; Harland N Sather; Stephen P Hunger; Peter G Steinherz; Paul S Gaynon; Nita L Seibel
Journal:  Lancet Oncol       Date:  2012-08-15       Impact factor: 41.316

Review 5.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

6.  Genetics of pleiotropic effects of dexamethasone.

Authors:  Laura B Ramsey; Stan Pounds; Cheng Cheng; Xueyuan Cao; Wenjian Yang; Colton Smith; Seth E Karol; Chengcheng Liu; John C Panetta; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Raul C Ribeiro; John T Sandlund; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

7.  Osteonecrosis of the femoral head in childhood malignancy.

Authors:  Stephanie W Mayer; Braden K Mayer; J Mack Aldridge; James R Urbaniak; Robert D Fitch; Robert K Lark
Journal:  J Child Orthop       Date:  2012-12-25       Impact factor: 1.548

8.  Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.

Authors:  Seth E Karol; Leonard A Mattano; Wenjian Yang; Kelly W Maloney; Colton Smith; ChengCheng Liu; Laura B Ramsey; Christian A Fernandez; Tamara Y Chang; Geoffrey Neale; Cheng Cheng; Elaine Mardis; Robert Fulton; Paul Scheet; F Anthony San Lucas; Eric C Larsen; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Meenakshi Devidas; Mary V Relling
Journal:  Blood       Date:  2015-11-20       Impact factor: 22.113

9.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Authors:  Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Jane O'Brien; Suzanne E Dahlberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Marshall Schorin; Mary V Relling; Harvey J Cohen; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

Review 10.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 2: imaging of complications of cancer treatment.

Authors:  I Zerizer; P D Humphries
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.